BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2019 9:05:36 AM | Browse: 623 | Download: 1034
 |
Received |
|
2019-02-10 08:29 |
|
Peer-Review Started |
|
2019-02-12 01:23 |
|
To Make the First Decision |
|
2019-03-20 06:32 |
|
Return for Revision |
|
2019-03-20 08:09 |
|
Revised |
|
2019-04-12 11:33 |
|
Second Decision |
|
2019-04-28 09:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-04-29 10:21 |
|
Articles in Press |
|
2019-04-29 10:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-16 00:37 |
|
Publish the Manuscript Online |
|
2019-05-20 09:05 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hidekatsu Kuroda, Tamami Abe, Yudai Fujiwara, Takuya Okamoto, Miki Yonezawa, Hiroki Sato, Kei Endo, Takayoshi Oikawa, Kei Sawara and Yasuhiro Takikawa |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hidekatsu Kuroda, MD, PhD, Doctor, Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Uchimaru19-1, Morioka 020-8505, Iwate, Japan. hikuro@iwate-med.ac.jp |
| Key Words |
Hepatocellular carcinoma; Lenvatinib; Contrast-enhanced ultrasound; Time-intensity curve |
| Core Tip |
Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imaging biomarkers of lenvatinib efficacy. The rate of change for TIC parameters showed precisely reflect the therapeutic effects. CEUS may be useful for the early prediction of tumor response to lenvatinib therapy in patients with unresectable HCC. |
| Publish Date |
2019-05-20 09:05 |
| Citation |
Kuorda H , Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i19.2365 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
